CureVac Shares Officially Delisted Following BioNTech Acquisition

CureVac NL0015436031

The standalone trading journey of CureVac has reached its conclusion. The biotechnology firm has now been formally removed from the Nasdaq exchange, marking the final step in its acquisition by industry peer BioNTech. The delisting, which took effect on Friday, sees the ticker symbol "CVAC" retired and all trading activity permanently ceased.

This move completes a process that began in early January following the finalization of the takeover. CureVac has submitted a Form 25 to the U.S. Securities and Exchange Commission (SEC), effectively terminating its reporting obligations. The company now operates as a wholly-owned subsidiary of BioNTech.

The consolidation transfers CureVac's entire mRNA technology platform and patent portfolio into the development pipeline of its new parent company. This structural shift removes CureVac as an independent competitor in the mRNA sector, consolidating assets under the BioNTech umbrella.

Key elements of the finalized transaction include:
* Exchange Status: Official delisting from Nasdaq as of Friday.
* Trading Activity: All share trading, suspended since January, is now permanently terminated with shares annulled.
* Ownership: BioNTech now holds full control over CureVac's assets and operational activities.

Market Focus Shifts to BioNTech's Strategy

With CureVac's exit from the public market, investor attention turns squarely to BioNTech's post-acquisition strategy. In a notable development on Friday, analysts at Goldman Sachs upgraded BioNTech's stock to a "Buy" rating. The upgrade cited a strengthened oncology pipeline and the strategic value of combining the mRNA platforms of both companies.

Market observers anticipate the integration will accelerate development in cancer immunotherapies, a field where the two firms were previously rivals. The merger also resolves previous legal disputes between the entities and consolidates research resources. This positions BioNTech more favorably to achieve critical clinical milestones targeted for 2026.

Outcome for Former Shareholders

For investors, the CureVac investment chapter is now closed. Former shareholders who accepted the acquisition offer now hold BioNTech equity or have received cash compensation according to the offer's terms. The future economic return from this merger will be solely reflected in the performance of BioNTech's shares and the progress of its expanded research and development pipeline.